|
Characteristics
| |
PFS
|
CSS
|
OS
|
|---|
|
N
|
2-year rate
|
P-value
|
2-year rate
|
P-value
|
2-year rate
|
P-value
|
|---|
|
Age
| | |
0.62
| |
0.43
| |
0.58
|
|
<75
|
50
|
20
| |
54
| |
40
| |
|
≥75
|
33
|
27
| |
61
| |
36
| |
|
Sex
| | |
0.82
| |
0.49
| |
0.86
|
|
M
|
75
|
23
| |
43
| |
39
| |
|
F
|
8
|
25
| |
64
| |
38
| |
|
ECOG PS
| | |
0.53
| |
0.28
| |
0.20
|
|
0-1
|
43
|
23
| |
59
| |
44
| |
|
2-3
|
40
|
23
| |
53
| |
33
| |
|
aFEV1(%)
| | |
0.84
| |
0.96
| |
0.69
|
|
≥70
|
45
|
22
| |
50
| |
47
| |
|
<70
|
33
|
24
| |
46
| |
40
| |
|
Pathology
| | |
0.81
| |
0.92
| |
0.71
|
|
Squamous cell carcinoma
|
62
|
24
| |
60
| |
63
| |
|
Adenocarcinoma
|
13
|
23
| |
35
| |
23
| |
|
Others
|
8
|
13
| |
60
| |
38
| |
|
Tumor size
| | |
0.32
| |
0.9
| |
0.37
|
|
<7 c m
|
66
|
18
| |
57
| |
36
| |
|
≥7 c m
|
17
|
41
| |
55
| |
47
| |
|
T-stage
| | |
0.14
| |
0.13
| |
0.2
|
|
1-2
|
33
|
27
| |
63
| |
39
| |
|
3-4
|
50
|
20
| |
53
| |
38
| |
|
N-stage
| | |
0.55
| |
0.67
| |
0.55
|
|
0-1
|
27
|
30
| |
64
| |
44
| |
|
2-3
|
56
|
20
| |
53
| |
36
| |
|
Initial response
| | |
0.11
| |
0.07
| |
0.17
|
|
CR or PR
|
49
|
29
| |
71
| |
49
| |
|
SD or PD
|
34
|
15
| |
35
| |
24
| |
-
Abbreviations: PFS progession-free survival, CSS cause-specific survival, OS overall survival, ECOG PS Eastern Cooperative Oncology Group performance status, FEV1 forced expiratory volume in one second, CR complete response, PR partial response, SD stable disease, PD progressive disease
-
aFEV1 test was not performed in 5 patients
